Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand

Alberto D’Angelo, Stefan Bagby, Ilaria Camilla Galli, Carlotta Bortoletti, Giandomenico Roviello

Research output: Contribution to journalReview article

Abstract

Introduction: Erdafitinib is the first orally administered pan-fibroblast growth factor receptor (FGFR) kinase inhibitor approved by the Food and Drug Administration (FDA). Areas covered: Specifically binding to FGFR family (FGFR-1 to FGFR-4), erdafitinib leads to reduced cell signaling and cellular apoptosis. Coupled with the ability to bind to vascular endothelial growth factor 2 (VEGFR-2), KIT, Fms-related tyrosine kinase 4 (FLT4), platelet-derived growth factor receptor α and β (PDGFR-α and PDGFR-β), RET and colony-stimulating factor 1 receptor (CSF-1 R), erdafitinib has further reported antitumor features causing cell killing. Expert opinion: In this review, we provide a comprehensive overview of erdafitinib chemical structure, pharmacologic properties, and current knowledge of clinical efficacy in the treatment of locally advanced or metastatic urothelial carcinoma. This treatment, recently approved in the U.S., is available for adult patients harboring FGFR2/FGFR3 genetic alterations who progressed within 12 months of an adjuvant or neoadjuvant chemotherapy regimen including platinum or progressed during or after prior a chemotherapy regimen including platinum.

Original languageEnglish
Pages (from-to)1139-1146
JournalExpert Review of Clinical Pharmacology
Volume13
Issue number10
Early online date6 Oct 2020
DOIs
Publication statusPublished - 2020

Keywords

  • bladder cancer therapy
  • erdafitinib
  • FGFR mutations
  • genitourinary cancer therapy
  • pan-FGFR inhibitors
  • solid tumors
  • toxicity
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand'. Together they form a unique fingerprint.

Cite this